Compare Quest Diagnostics Inc (DGX) vs Kraft Heinz Co (KHC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Kraft Heinz Co — how do they compare? Quest Diagnostics Inc trades at $237.32 (market cap $26.21B), while Kraft Heinz Co trades at $24.22 (market cap $29.23B). The key difference: Quest Diagnostics Inc and Kraft Heinz Co are close in size by market cap, and Kraft Heinz Co pays the higher dividend (6.49%). Which is the better fit depends on your goals.
| DGX | KHC | |
|---|---|---|
Market Cap | $26.21B | $29.23B |
Sector | Health | Consumer Staples |
52-Week High | $238.50 | $28.06 |
52-Week Low | $173.49 | $21.21 |
Enterprise Value | $31.97B | $45.55B |
Dividend Yield | 1.45% | 6.49% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $237.63, down slightly by 0.3% today, but maintains strong momentum with three consecutive quarterly earnings beats and a raised 2026 outlook. The stock shows bullish technical signals with moving averages supporting upward trends, while fundamentals reveal solid revenue growth to $11.04 billion in 2025 and improving profit margins. Recent news highlights surging testing demand and AI implementation driving operational efficiency.
DGX presents a favorable investment case with analyst consensus price target of $249.50 offering 5% upside potential. Strong testing demand, strategic partnerships, and earnings momentum support growth, though elevated debt levels and margin pressures from lower-margin deals pose moderate risks. The stock's current valuation at 25.21 P/E appears reasonable given growth prospects.
Kraft Heinz (KHC) trades at $24.93, down 1.54% on the day, with a bearish technical signal and mixed fundamentals. The company reported three consecutive quarterly earnings beats but faces profitability challenges with a negative net income margin of -13.64% and ROE of -8.78%. Recent news highlights CEO Steve Cahillane's turnaround strategy with increased marketing investments, while analysts remain cautious with only 11.43% buy ratings.
The stock presents a value opportunity with attractive valuation ratios (P/E 13.04, P/B 0.81) and 6.4% dividend yield, but significant risks include ongoing earnings erosion, competitive pressures, and high debt levels. The consensus price target of $24.00 suggests limited upside from current levels, requiring careful monitoring of the company's execution on its growth strategy.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Kraft Heinz Co
In July 2015, Kraft merged with Heinz to create the third-largest food and beverage manufacturer in North America behind PepsiCo and Nestle and the fifth-largest player in the world. Beyond its namesake brands, the combined firm's portfolio includes Oscar Mayer, Velveeta, and Philadelphia. Outside North America, the firm's global reach includes a distribution network in Europe and emerging markets that drive around one fifth of its consolidated sales base, as its products are sold in more than 190 countries and territories.
Read more on KHC →
